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Purpose: Variation exists in cooperative group recommendations for the dorsal border for the chest
wall clinical target volume (CTV). We aimed to quantify the impact of this variation on doses to
critical organs and examine patterns of chest wall recurrence relative to the pectoralis muscle.
Methods and Materials: We retrospectively assessed patterns of chest wall recurrence quantiﬁed to
the recommended CTV borders for women treated between 2005 and 2017. We compared treatment plans for 5 women who were treated with left postmastectomy radiation therapy, with the
chest wall contoured using varying dorsal borders for CTV: (1) Anterior pleural surface (Radiation
Therapy Oncology Group), (2) anterior surface of pectoralis major (European Society for Radiotherapy and Oncology), and (3) anterior rib surface (institutional practice). Treatment plans were
generated for 50 Gy in 25 fractions. Doses to organs-at-risk were compared using paired-sample t
tests.
Results: Institutional patterns of chest wall recurrence were 64.7% skin and subcutaneous tissue,
23.5% both anterior to and between the pectoralis muscles, and 11.8% isolated to the tissue between the pectoralis major and minor. No chest wall recurrences were noted deep to pectoralis
minor. When comparing the plans generated per the Radiation Therapy Oncology Group versus
European Society for Radiotherapy and Oncology contouring guidelines, the mean lung V20Gy,
heart mean dose, and left anterior descending artery mean dose were 33.5% versus 29.4%
(P < .01), 5.2 Gy versus 3.2Gy (P Z .02), and 27.3Gy versus 17.8Gy (P Z .04), respectively.
Conclusions: The recommended variations in the dorsal chest wall CTV border have signiﬁcant
impact on doses to the heart and lungs. Although our study was limited by small numbers, our
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institutional patterns of recurrence would support a more anterior dorsal border for the chest wall
CTV consistent with older literature.
Ó 2018 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation
Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Radiation oncology has undergone a great renaissance
transition from 2- to 3-dimensional planning to better
conform dose to the target and spare organs at risk.
However, the beneﬁts of 3-dimensional planning hinge on
the accurate identiﬁcation of the clinical target volume
(CTV). Cooperative groups have published contouring
guidelines with recommendations for CTV design to
better guide the application of postmastectomy radiation
therapy.1,2 These guidelines were predominately formulated based on expert opinion rather than clinical outcomes,3 and considerable variation exists in the
recommended dorsal border of the chest wall CTV between the guidelines.
The Radiation Therapy Oncology Group (RTOG)
recommends that the dorsal CTV border include the entire
thickness of the chest wall to the pleural surface to target
the skin, subcutaneous tissues, pectoralis major, pectoralis
minor, ribs, and intercostal muscles.1 Conversely, the
European Society for Radiotherapy and Oncology
(ESTRO) recommends that the dorsal CTV border
include the skin and subcutaneous tissue to the anterior
surface of pectoralis major, and only recommends inclusion of the pectoralis muscles and ribs in the setting of
documented invasion for T4a and T4c tumors.2 Similarly,
the RADCOMP Consortium trial (NCT02603341) breast
contouring guidelines recommend that the dorsal CTV
border extends posteriorly to, but not including, the ribs.
Recent pattern-of-care analyses have examined the
impact of this variation of patterns of recurrence, and
documented a signiﬁcant number of recurrences that
occurred outside of the smaller ESTRO, but within the
larger RTOG volumes.4 However, despite modern planning techniques, the increase in the treatment volume
from the RTOG CTV recommendations relative to traditional 2-dimensional postmastectomy radiation therapy
comes at a cost of signiﬁcant increases in the doses to the
heart and lungs.5 Any beneﬁts from postmastectomy radiation therapy in reducing locoregional recurrences that
translate into improved overall survival have to be
balanced against the potential risks of long-term sequelae,
including cardiac-related mortality.6,7 We have previously
proposed a compromised dorsal border for the chest wall
CTV of the anterior rib surface to include the skin, subcutaneous tissues, and pectoralis muscles based on a
literature review of patterns of recurrence in older
literature.3,8

Contemporaneous to the improvements in radiation
delivery, improvements in mammographic screening,
systemic therapy, and image guided surgical techniques
have reduced the risks of locoregional recurrence in breast
cancer in the modern era. A reduction in the absolute risks
of recurrence can also occur with a change in patterns of
chest wall recurrence, which has strong implications for
chest wall CTV design. Thus, we aimed to quantify the
impact of the recommended variation of the dorsal chest
wall CTV border on doses to critical organs and examined
the patterns of chest wall recurrence relative to the pectoralis muscle. We hypothesized that the majority of recurrences in the modern era occur anterior to the rib
surface, and a reduction in the dorsal chest wall CTV
border might decrease normal tissue exposure to the heart
and lungs.

Methods and Materials
After institutional review board approval, we used a
prospectively maintained, institutional, breast cancer
database and identiﬁed patients who were evaluated for
surgical resection of chest wall recurrence between 2005
and 2017. We reviewed the location of the recurrence
noted on the preoperative imaging or postoperative pathology results quantiﬁed in relation to the recommended
dorsal CTV borders.
Patients with nodal recurrence in the absence of disease recurrence in the chest wall were excluded, but patients with chest wall recurrence in the setting of lymph
node or distant metastases were included. If preoperative
imaging or postoperative pathology results were not
available to discern the location of chest wall recurrence
relative to the recommended CTV borders, patients were
also excluded. The baseline characteristics for patients
with chest wall recurrences in the anterior skin and subcutaneous tissues were compared with those of patients
with recurrences that involved the pectoralis muscles
using an c2 analysis with SPSS, version 24 (IBM
Cooperation, Armonk, NY).
Subsequently, we retrospectively created treatment
plans for 5 women treated with comprehensive postmastectomy radiation therapy to the left chest wall,
undissected axilla, supraclavicular, and internal mammary
lymph nodes. The chest wall was contoured using varying
dorsal borders for CTV, as recommended in the literature:
(1) Anterior pleural surface (per RTOG guidelines), (2)
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anterior surface of pectoralis major (per ESTRO guidelines), and (3) anterior rib surface to include both pectoralis major and minor (institutional practice). Treatment
plans were generated for 50 Gy in 25 fractions with goals
to meet the criteria for target volume coverage as recommended in the NSABP-B51 study. All plans were
created using partially wide tangents with a single isocenter ﬁeld-in-ﬁeld technique. Priority was given to target
coverage over critical organ dosimetry to allow for
normalization of the plans across the varying CTV deﬁnitions. The doses to the organs at risk were compared
between the plans using paired-sample t tests with SPSS,
version 24 (IBM cooperation, Armonk, NY).

Results
From 2005 to 2017, we retrospectively reviewed 69
patients who were evaluated for surgical resection of chest
wall recurrence, and identiﬁed 17 patients with chest wall
recurrence that met our inclusion criteria. The baseline
characteristics of the 17 patients identiﬁed with chest wall
recurrences are detailed in Table 1. Most recurrences were
invasive ductal carcinoma (71%), 82% were disease stage
II or III, and the most common subtype was estrogen

Table 1 Baseline patient characteristics for patient with
chest wall recurrence
Baseline characteristics
Laterality
Left
Right
Histology
Invasive ductal carcinoma
Invasive lobular carcinoma
Inﬂammatory
Age, years
<57
58
Initial disease stage
I
II
III
Unrecorded
Subtype
ER þ PR þ HER2ER þ PR þ HER2þ
ER-PR-HER2þ
ER-PR-HER2Unrecorded
Prior irradiation
No
Yes
Unrecorded

N (%)
12 (71%)
5 (29%)
12 (71%)
2 (12%)
3 (18%)
10 (59%)
7 (41%)
1
7
7
2

(6%)
(41%)
(41%)
(12%)

8
0
2
5
2

(47%)
(0%)
(12%)
(29%)
(12%)

8 (47%)
4 (24%)
5 (29%)

Abbreviations: ER Z estrogen receptor; HER2 Z human epidermal
growth factor receptor 2; PR Z progesterone receptor.
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receptor þ progesterone receptor þ human epidermal
growth factor receptor 2 negative (47%). The median age
at the time of diagnosis was 57 years (interquartile range,
42-57 years). The median time to chest wall recurrence
from the time of diagnosis was 2.25 years (interquartile
range, 1.29-5.70 years).
Recurrences were examined by comparing the
anatomic borders used by the consensus guidelines:
Anterior to the pectoralis major (ESTRO guidelines),
below pectoralis major and minor but to the anterior rib
surface (institutional variation), and anterior pleural surface (RTOG guidelines; Fig 1A). When examining the
anatomic location of chest wall recurrences, 64.7% of
recurrences were isolated to tissue anterior to the pectoralis muscle, 23.5% both anterior to and between the
pectoralis muscles, and only 11.8% were isolated to the
tissue between the pectoralis major and minor (Fig 1B).
There were no chest wall recurrences noted deep to the
pectoralis minor. There were no differences in patterns of
recurrence by laterality, histology, age, stage, receptor
subtype, or prior irradiation (Table 2).
Next, we aimed to quantify the impact of the dorsal
CTV border variation on doses to critical organs. We
created treatment plans that covered the chest wall,
undissected axilla, supraclavicular, and internal mammary
lymph nodes for 5 women who underwent left-sided
mastectomies. Table 3 summarizes the baseline characteristics for these patients. We varied the dorsal CTV
border according to the RTOG, ESTRO, and institutional
variation protocols (Figs 2A-E). Figure 3 summarizes the
impact of the varying dorsal borders for critical organ
dosimetry.
When comparing the RTOG versus ESTRO-generated
contouring guideline plans, we found that the mean lung
V20Gy, heart mean dose, and left anterior descending
artery mean doses were 33.5% versus 29.4% (P < .01),
5.2 Gy versus 3.2 Gy (P Z .02), and 27.3 Gy versus 17.8
Gy (P Z .04), respectively. When comparing the RTOG
versus our institutional variation-generated contouring
guideline plans, we found that the mean lung V20Gy,
heart mean dose, and left anterior descending artery mean
doses were 33.5% versus 31.4% (P Z .01), 5.2 Gy versus
3.8 Gy (P Z .03), and 27.3 Gy versus 22.6 Gy (P Z .12),
respectively.

Discussion
Increasing the dorsal border for the chest wall CTV
increases the doses to the heart and lungs as quantiﬁed
herein, with an increase in the mean heart dose of 2 Gy
and lung V20Gy of 4% for plans generated with the
RTOG compared with the ESTRO-contouring guidelines.
Although no recurrences deep to the pectoralis were
identiﬁed, 35% of chest wall recurrences were noted in
regions not routinely included in the ESTRO chest wall
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A

B

Anterior Chest Wall

Skin and subcutaneous ssue

Instuonal
Recurrences
7
75
5%
75%

ESTRO CTV
Instuonal Variant CTV

64.7%

Anterior to pectoralis
major only

23.5%

Anterior to pectoralis major
and between the pectoralis
major and minor

RTOG CTV
Pectoralis Major

Pectoralis Minor
75%
7
5%
%
Intercostal Muscles
Ribs

11.8%

Only between the pectoralis
major and minor

0.0%

Posterior to pectoralis minor

Figure 1 Chest wall anatomy relative to (A) contorting recommendations for clinical target volume design and (B) institutional
patterns of chest wall recurrence postmastectomy. CTV, clinical target volume.

CTV, either between the pectoralis muscles or extending
to both the pectoralis and subcutaneous tissues anterior to
pectoralis major. However, 100% of recurrences would
Table 2 Comparative patterns of recurrence by baseline
characteristics

Laterality
Left
Right
Histology
Invasive ductal
carcinoma
Invasive lobular
carcinoma
Inﬂammatory
Age, years
<57
58
Initial disease stage
(n Z 15)
I
II
III
Subtype (n Z 15)
ER þ PR þ HER2ER þ PR þ HER2 þ
ER-PR-HER2 þ
ER-PR-HER2Prior irradiation
(n Z 12)
No
Yes

Anterior
recurrence
(n Z 11)

Pectoralis
recurrence
(n Z 6)

7 (64%)
4 (36%)

5 (83%)
1 (17%)

7 (64%)

5 (83%)

1 (9%)

1 (17%)

3 (27%)

0 (0%)

6 (55%)
5 (46%)

4 (67%)
2 (33%)

P-value

0.39

0.36

0.63

0.39
0 (0%)
4 (44%)
5 (56%)

1 (17%)
3 (50%)
2 (33%)

5
0
1
4

3
0
1
1

0.70
(50%)
(0%)
(10%)
(40%)

(60%)
(0%)
(20%)
(20%)
0.16

5 (56%)
4 (44%)

3 (100%)
0 (0%)

Abbreviations: ER Z estrogen receptor; HER2 Z human epidermal
growth factor receptor 2; PR Z progesterone receptor.

have been within a modiﬁed dorsal chest wall CTV
border of the anterior rib surface, which reduced the mean
heart dose by 1.4 Gy and mean lung V20Gy by 2%
compared with the RTOG dorsal CTV border of the
anterior pleural surface. Thus, with no recurrences deep to
the pectoralis muscle, this dorsal CTV border might
represent a potential compromise in maximizing the
coverage of tissues at risk while minimizing exposure to
normal organs.
We previously retrospectively analyzed patterns of
recurrence based on a literature review of 278 cases
identiﬁed from studies published between 1966 and 2003,
and highlighted that 72% to 100% of chest wall recurrences occurred in the skin or subcutaneous tissues and
no recurrences were identiﬁed deep to pectoralis.3 However, a number of questions remained in terms of how
these patterns of recurrence held in the context of modern
systemic therapy. For example, given that deep chest wall
recurrences do occur, are these publications (predominantly surgical series) biased toward more superﬁcial
recurrences?9
More recently, a Korean multi-institutional analysis
has shed further light on patterns of recurrence in the
modern era.10 With 234 patients and 337 recurrences, the
researchers identiﬁed 25 patients with 29 chest wall recurrences in patients undergoing mastectomy. The patterns of recurrence were identical to those previously
identiﬁed in our literature review, with 76% in the skin or
subcutaneous tissues, 24% within the pectoralis muscle,
and 0% deep to the pectoralis in the ribs or intercostal
muscles. Combined, these experiences are further validated by the patterns of chest wall recurrences noted
herein (Fig 1B), and would potentially support the hypothesis that the epicenter for deep chest wall recurrences
noted in series of full thickness chest wall resections is not
in the ribs and intercostal spaces, but are a reﬂection of a
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Baseline patient characteristics for chest wall planning patients

Age Pathology TNM Stage

Clinical/ ER PR HER2 No. of Location Size
positive of tumor
pathologic
LNs
Stage

A 40 ILC

pT3 N1a M0 pIIIa

þ þ -

2/4

B 59 IDC

pT2 N0 Mx

þ -

-

0/15

C 79 mixed
pT2 N2a M0 pIIIa
IDC/ILC

þ þ -

5/11

D 41 IDC

T1 N1 M0, cIIa
ypT0N0M0

þ þ -

0/16

E 59 IDC

pT2N1a

þ þ -

1/1

pII

pIIa

Left

Surgery

Reconstruction

7.0 cm

Left total
Immediate
mastectomy
implant-based
Left
4.5 cm
Left modiﬁed
None
radical mastectomy
Delayed
Bilateral 3.1 cm
Bilateral skin
multifocal sparing mastectomy immediate
reconstruction
with left axillary
dissection and right with bilateral
tissue
sentinel LN
expander
placement
Left
no residual Left modiﬁed radical None
invasive
mastectomy and
carcinoma right prophylactic
mastectomy with
sentinel lymph
node
Left
4.0 cm
Left simple
Immediate
mastectomy
implant-based
with sentinel LN

Abbreviations: ER Z estrogen receptor; HER2 Z human epidermal growth factor receptor 2; IDC Z invasive ductal carcinoma; ILC Z invasive
lobular carcinoma; LN Z lymph node; PR Z progesterone receptor.

direct invasion from recurrences starting in the skin,
subcutaneous tissues, and pectoralis progressing in the
setting of multiple prior recurrences, reirradiation, and
large ulcerative lesions.11e13
Taken together, the prior literature review, multiinstitutional Korean data, and patterns of recurrence presented herein are consistent in that patterns of recurrence
do not support a need for the routine inclusion of the ribs
and intercostal muscles in the chest wall CTV as recommended in the RTOG contouring guidelines for postmastectomy radiation therapy. However, 24% to 35% of
recurrences that occur between the pectoralis major and

minor might be potentially missed with the more anterior
CTV border recommended by the ESTRO guidelines.3,10
We recognized that increases in the depth of the CTV
would have compromises in the doses to the heart and
lungs (see Figure 3); therefore, we attempted to quantify
the impact of these differences in CTV design on heart
and lung exposure, and showed a signiﬁcant increase in
mean heart dose of 2 Gy and lung V20Gy of 4% when
comparing the RTOG versus ESTRO-based plans. Thus,
the question remains: Is this trade off in terms of
increased risks of recurrence worth this difference in
normal tissue exposure?

Figure 2 Contouring examples for postmastectomy radiation therapy. Red: Radiation Therapy Oncology Group guidelines; yellow:
European Society for Radiation therapy and Oncology guidelines; green: institutional variation.
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Target Volume Coverage across Consensus Guidelines
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Figure 3 Target volume coverage for treatment plans across consensus guidelines. NS, not statistically signiﬁcant with P > .05.
)Radiation Technology Oncology Group versus European Society for Radiation therapy and Oncology P < .05; yRadiation Technology
Oncology Group versus institutional variation, P < .05. Ax, undissected axillary lymph nodes; Clung V5, contralateral lung volume
receiving 5 Gy; CW, chest wall. IMN, internal mammary lymph nodes; LAD, left anterior descending artery; Lung V5, ipsilateral lung
volume receiving 5Gy; Lung V10, ipsilateral lung volume receiving 10 Gy; lung V20, ipsilateral lung volume receiving 20 Gy; SCL,
supraclavicular lymph nodes; V15, volume receiving 15 Gy; V25, volume receiving 25 Gy; V30, volume receiving 30 Gy.
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Our institutional practice of a compromised dorsal
border of the anterior rib surface to include both pectoralis
major and minor would have included 100% of the recurrences in our prior literature review, the Korean multiinstitutional data, and the patterns of recurrence presented
herein. We believe that increasing the mean heart dose by
only 0.6 Gy and lung V20Gy by 2% relative to the
ESTRO-based plans represents a reasonable clinical
compromise (Figs 1 and 3). Others have suggested that
the application of a deeper dorsal border be individualized
based on patients’ perceived risks of heart and lung
toxicity relative to comorbidities such as smoking and
other preexisting cardiopulmonary risk factors.14,15
This may also represent a reasonable clinical application of this data. More work is needed to better elucidate
which subgroups might be at the highest risk of deep
chest wall recurrence, such as inﬂammatory breast cancer
or triple negative subtypes, because no differences were
noted in patterns of recurrence by baseline characteristics.16,17 Furthermore, this study cannot speak to the implications for use of skin bolus in the postmastectomy
setting, which varies at our institution, but is commonly
applied, usually in an every-other-day fashion or daily
until a Grade 2 reaction develops.18
This study is limited by inherent biases in retrospective
design and small patient numbers, which limit the power
of the study to detect small differences between groups.
The patients included in our patterns-of-recurrence analysis were identiﬁed from a surgical database, and this
might have biased the inclusion toward smaller chest wall
recurrences. However, patients with large recurrences,
even in the setting of metastatic disease who were evaluated for palliative resection, were included and identiﬁed
in this database, and the patterns of recurrence were
consistent with those of other larger series, which suggests that the impact of this bias is small, if any.3,10
This analysis speciﬁcally does not take into account
other modern radiation therapy techniques, such as deepinspiration breath hold (routinely used at our institution in
postmastectomy radiation therapy to achieve a mean heart
dose <2 Gy but not used in the presented study) or proton
beam radiation therapy, which might be able to further
reduce the doses to the heart and lungs and thereby widen
the therapeutic ratio toward the CTV coverage of deeper
chest wall targets.19,20
Ongoing trials, such as the RADCOMP Consortium
trial (NCT02603341), that compare proton versus photon
radiation therapy in breast cancer will help better elucidate if such techniques might indeed translate into clinically meaningful reductions in doses to the heart and
lungs. In the interim, given the salient differences that
exist in international consensus contouring deﬁnitions and
the implications of these variations on target coverage
relative to patterns of chest wall recurrence and normal
tissue exposure, more studies are clearly needed to help
better reach an international consensus for CTV design.
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Until such a consensus is reached, the current variation in
CTV will challenge clinical practice and the interpretation
of prospective clinical studies across groups.

Conclusions
Patterns of chest wall recurrence in the modern era are
predominately in the skin and subcutaneous tissues, followed by recurrences within the pectoralis muscle. Isolated recurrences deep to the pectoralis are uncommon,
and routine inclusion of the ribs and intercostal muscles in
the chest wall CTV might not be necessary for routine
applications of postmastectomy radiation therapy. Inclusion of the ribs and intercostal muscles in the chest wall
CTV as recommended by the RTOG contouring guidelines signiﬁcantly increase the doses to the heart and lungs
compared with the more anterior border of the pectoralis
major as recommended by the ESTRO contouring
guidelines, which may miss chest wall recurrences within
the pectoralis muscles.
Thus, we recommend a compromised dorsal border of
the anterior rib surface, which will signiﬁcantly reduce
doses to the heart and lungs relative to the RTOG deﬁnition and be more consistent with patterns of chest wall
recurrence than those per the ESTRO deﬁnition.
Continued study and an international consensus are needed
to help better guide clinical practice and trial design.
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